The operation was co-led by Panakes Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and the Business Angels of Club degli Investitori through Simon Fiduciaria.

Born as a spin-off from EPFL and CHUV in Lausanne, Lymphatica Medtech is developing LymphoDrain, a revolutionary implantable device for the treatment of lymphedema, a chronic vascular condition affecting millions of people worldwide.

The Lymphatica Medtech team, led by CEO and co-founder Dr. Marco Pisano and COO and co-founder Valentina Triacca, has developed an innovative technology that promises to transform the lives of patients affected by lymphedema.

This investment will accelerate the clinical development and validation of LymphoDrain, as well as support the expansion of R&D activities, production, and clinical operations through the opening of a branch in Italy.

“Lymphatica addresses a clear need of patients affected by lymphedema in the arm or leg, proposing an innovative, simple, and effective solution, potentially capable of significantly improving quality of life,” state Luca Porro and Alice Ravizza, Champions of Club degli Investitori.

Thanks to our Champions, Luca and Alice, and to Arianna Floris, Senior Analyst at Club degli Investitori who managed the operation on behalf of the Club’s members.